A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema (NCT06807281)
A Phase 3, Multicenter, Long-Term, Open Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic Dermatitis
🩺 Plain-English Summary (8th-Grade Level)
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.
Who can join: Review the eligibility criteria below.
Location: Cahaba Dermatology & Skin Health Center — Birmingham, Alabama
Age range: 2 Years to 11 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (38 Sites)
Showing the first 25 of 38 sites.
- Cahaba Dermatology & Skin Health Center — Birmingham, Alabama
- Arkansas Research Trials — North Little Rock, Arkansas
- Investigational Drug Service - Rady Childrens Hospital-San Diego — San Diego, California
- University of California, San Diego/ Rady Children's Hospital - San Diego — San Diego, California
- Solutions Through Advanced Research — Jacksonville, Florida
- Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana
- Saint Louis University — St Louis, Missouri
- Medical University of South Carolina - South Carolina Translational Research Nexus Clinic — Charleston, South Carolina
- Tribe Clinical Research, LLC — Greenville, South Carolina
- Texas Dermatology and Laser Specialists — San Antonio, Texas
- Beijing Children's hospital, Capital Medical University — Beijing, Beijing Municipality
- Shenzhen Children's Hospital — Shenzhen, Guangdong
- Hunan Children's Hospital — Changsha, Hunan
- Dermatology Hospital of Jiangxi Province — Nanchang, Jiangxi
- Hangzhou Third People's Hospital — Hangzhou, Zhejiang
- Shanghai Children's Hospital — Shanghai,
- Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine — Shanghai,
- Universitätsklinikum Münster — Münster, North Rhine-Westphalia
- Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden — Dresden, Saxony
- Pécsi Tudományegyetem Klinikai Központ — Pécs, Baranya
- Clinexpert Kft. — Budapest, Pest County
- Queen's square Medical Facilities Queen's square Dermatology and Allergology — Yokohama, Kanagawa
- Dermatology and Ophthalmology Kume Clinic — Sakai, Osaka
- Sasamoto Children's Clinic — Setagaya-ku, Tokyo
- Fukuoka National Hospital — Fukuoka,
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
- ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
- A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
- Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
- A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California
Explore by condition: All Atopic Dermatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.